Download the Agenda


Speaker Information

 Roy Baynes
Roy Baynes Senior VP, Global Clinical Development Merck, Sharp & Dohme


Main Conference Day 1

12:20 PM KEYNOTE ADDRESS: Gain an Overview of the Past, Present, and Future of Immune Checkpoint Modulation: What Has Already Been Accomplished, And What Is To Come?

• Reviewing the development of this revolutionary new
treatment
• Assessing the monoclonal and combination potential of
immune checkpoint inhibitors
• Overview of the developmental stages of immune checkpoint
inhibitors, from preclinical, to development, to approval
• Identifying the critical issues facing the development of cancer
immunotherapies and how we can overcome these issues
• Highlighting the importance of collaboration between
industry, academia, regulators, and advocacy groups to
advance cancer immunotherapies

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!

IDGA

Become a Pharma IQ Member and receive our weekly newsletter!